Skip to main content
. 2020 Oct 20;2020(10):CD011748. doi: 10.1002/14651858.CD011748.pub3

EVOLVD.

Study name Cholesterol lowering with EVOLocumab to prevent cardiac allograft vasculopathy in de‐novo heart transplant recipients (EVOLVD)
Methods Parallel arm RCT
Participants De novo heart transplant recipients
Interventions Evolocumab
Placebo
Outcomes  
Starting date November 2018
Contact information  
Notes